A phase 1b/2 open-label, ascending single and repeat dose clinical trial designed to evaluate the safety of light-activated Au-011 for the treatment of subjects with small to medium (2.0 mm 3.4 mm thickness) primary choroidal melanoma
Study of Safety of Light-Activated Au-011 for Treatment of Small to Medium Primary Choroidal Melanoma
Sponsor: Aura Biosciences
Enrolling: Male and Female Patients
IRB Number: AAAR2880
U.S. Govt. ID: NCT03052127
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to test the safety of Light-activated AU-011 at three different doses of the study drug and repeat dose regimens (two or three doses of highest safe dose) to find out what effects, if any, it has on research participants with a choroidal melanoma tumor. This study will have a high dose, a medium dose, and a low dose of Light-activated AU-011.
This study is closed
Investigator
Brian Marr, MD
Do You Qualify?
Have you been diagnosed with primary choroidal melanoma (CM)? Yes No
Do you use or require the use of heparin or low molecular weight heparins? Yes No
Do you have an active ocular infection (bacterial, viral, or fungal)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE